VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary reason for this study is to determine whether the addition of VELCADE
(bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to
disease progression (TTP) in subjects with previously untreated multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.